Sage Therapeutics’ Third Annual FutureCast Showcases Data from All Three Brain Health Franchises
December 14 2021 - 6:30AM
Business Wire
In the open-label LUMINARY Study, SAGE-718
improved performance from baseline on multiple tests of cognitive
function in patients with Alzheimer’s disease mild cognitive
impairment and mild dementia, consistent with positive signals seen
in Parkinson’s disease and Huntington’s disease
Now enrolling patients in KINETIC 2, a Phase 2b
dose-ranging study evaluating SAGE-324 in essential tremor
Webcast today at 8:00 a.m. ET
Today, Sage Therapeutics, Inc. (Nasdaq: SAGE), a
biopharmaceutical company committed to developing novel therapies
with the potential to transform the lives of people with
debilitating disorders of the brain, will host its third annual
“FutureCast: An R&D Portfolio Review” to showcase the Company’s
research and development strategy, and clinical progress in its
depression, neurology, and neuropsychiatry franchise programs.
“Sage’s expertise in brain circuitry, including our deep
understanding of the GABAA and NMDA receptor pathways, has resulted
in a rich portfolio that includes multiple opportunities to deliver
life-changing brain health medicines, if we’re successful,” said
Barry Greene, Chief Executive Officer at Sage Therapeutics. “Over
the last decade, the devastating impact of brain health disorders
and the absence of innovation have resulted in significant costs to
individuals, families, and society. We believe our productive,
proactive, predictive, and patient-focused approach to drug
development may enable us to deliver innovative treatments that
meet patient needs. We look forward to advancing this work in
2022.”
Clinical Program Updates:
Sage is advancing a portfolio of novel and differentiated product
candidates designed to improve brain health by targeting the GABA
and NMDA receptor systems. Dysfunction in these systems is known to
be at the core of numerous disorders.
FutureCast will feature the following topics and speakers:
Science of Sage: Expanding Our Leading Brain Health
Portfolio
- Barry Greene, Chief Executive Officer
Zuranolone: Program Overview
- Rob Lasser, M.D., Vice President, Late Development
SAGE-324: Patient-led Drug Development to Address the Unmet
Need in Essential Tremor
- Helen Colquhoun, M.D., Vice President, Early Development
SAGE-718 CogNEXT Platform: An Evolution of Sage’s Early-Stage
Clinical Signal-Finding Strategy
- Aaron Koenig, M.D., Vice President, Medical Lead
Neuropsychiatry
Advancing Our Differentiated Approach to Development
- Jim Doherty, Ph.D., Chief Development Officer
Webcast Information FutureCast: An R&D Portfolio
Review, begins at 8:00 a.m. ET today, Tuesday, December 14, 2021.
The live webcast can be accessed on the investor page of Sage's
website at investor.sagerx.com. A replay of the webcast will be
available on Sage's website approximately two hours after the
completion of the event and will be archived for up to 30 days.
About Sage Therapeutics Sage Therapeutics is a
biopharmaceutical company committed to developing novel therapies
with the potential to transform the lives of people with
debilitating disorders of the brain. We are pursuing new pathways
with the goal of improving brain health, and our depression,
neurology and neuropsychiatry franchise programs aim to change how
brain disorders are thought about and treated. Our mission is to
make medicines that matter so people can get better, sooner. For
more information, please visit www.sagerx.com.
Forward-Looking Statements Various statements in this
release concern Sage's future expectations, plans and prospects,
including without limitation: our views and expectations regarding
the potential of our product candidates in various indications, the
potential profile and benefit of our product candidates, the
potential of our drug development approach to lead to innovative
treatments, and the goals, opportunity and potential for our
business. These statements constitute forward-looking statements as
that term is defined in the Private Securities Litigation Reform
Act of 1995. These forward-looking statements are neither promises
nor guarantees of future performance, and are subject to a variety
of risks and uncertainties, many of which are beyond our control,
which could cause actual results to differ materially from those
contemplated in these forward-looking statements, including the
risks that: success in non-clinical studies or in prior clinical
trials of our product candidates may not be repeated or observed in
ongoing, planned or future studies; ongoing, planned and future
clinical trials may not meet their primary endpoints or key
secondary endpoints; non-clinical and clinical results from ongoing
or future trials may not support further development of the product
candidate or filing for or obtaining regulatory approval on the
timelines we expect or at all and we may be required to conduct
additional clinical trials or nonclinical studies which may not be
successful; we may experience slower than expected enrollment in
our clinical trials or may encounter other delays or problems,
including in analyzing data or requiring the need for additional
analysis, data or patients, and such issues with any trial could
cause delay in completion of the trial, availability of results and
timing of future activities; we may encounter unexpected safety or
tolerability issues with respect to any of our product candidates;
we may encounter different or more severe adverse events at the
higher doses, different frequency or length of dosing or in new
indications we are studying or may study in ongoing or planned
trials; the FDA and other regulatory authorities may ultimately
decide that the design or results of our completed, ongoing or
planned clinical trials for zuranolone or any of our other product
candidates, even if positive, are not sufficient to file for or
obtain regulatory approval in the indications that are the focus of
our development plans despite prior regulatory advice; at any
stage, regulatory authorities may ask for additional clinical
trials, nonclinical studies or other data in order for us to
proceed further in development or to file for or obtain regulatory
approval; other decisions or actions of the FDA or other regulatory
authorities may affect the initiation, timing, design, size,
progress and cost of clinical trials and our ability to proceed
with further development; we may never achieve the rate of new
product candidates from our research engine that we expect in the
future; even if our products are successfully developed and
approved, the number of patients with the diseases or disorders our
products treat, and the actual market for such products may be
smaller than our current estimates; or we may not achieve the
anticipated benefit of our product candidates or market acceptance
at acceptable levels; we may never be successful or achieve the
goals and opportunity of our business, as well as those risks more
fully discussed in the section entitled "Risk Factors" in our most
recent Quarterly Report on Form 10-Q, as well as discussions of
potential risks, uncertainties, and other important factors in our
subsequent filings with the Securities and Exchange Commission. In
addition, any forward-looking statements represent our views only
as of today and should not be relied upon as representing our views
as of any subsequent date. We explicitly disclaim any obligation to
update any forward-looking statements.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20211213006006/en/
Investors Helen Rubenstein 315-382-3919
helen.rubenstein@sagerx.com
Media Maureen L. Suda 617-949-4289
maureen.suda@sagerx.com
Sage Therapeutics (NASDAQ:SAGE)
Historical Stock Chart
From Aug 2024 to Sep 2024
Sage Therapeutics (NASDAQ:SAGE)
Historical Stock Chart
From Sep 2023 to Sep 2024